First-line treatment for locally advanced or metastatic urothelial carcinoma: a randomized controlled phase III study comparing pembrolizumab with and without platinum-based combination chemotherapy and chemotherapy alone in patients with advanced or metastatic urothelial carcinoma (Keynote-361) AB 54/16 of AUO

被引：0
|
作者：
Rexer, H. [1 ]
Ohlmann, C. -H. [2 ]
Retz, M. [3 ]
机构：
[1] AUO Geschaftsstelle, Seestr 11, D-17252 Schwarz, Germany
[2] Arbeitsgemeinschaft Urol Onkol Deutsch Krebsgesel, Organgrp Blasenkarzinom, Kuno Fischer Str 8, D-14057 Berlin, Germany
[3] Tech Univ Munich, Urol Klin & Poliklin, LKP, Klinikum Rdl, Ismaninger Str 22, D-81675 Munich, Germany
来源：
AKTUELLE UROLOGIE | 2018年 / 49卷 / 01期
关键词：
D O I：
10.1055/s-0043-125341
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：21 / 22
页数：2
相关论文
共 50 条
  • [1] First-line Therapy for locally advanced or metastatic Urothelial Carcinoma A randomized, controlled Phase-III-Trial comparing Pembrolizumab with or without platinum-based Combination Chemotherapy and Chemotherapy only in Patients with advanced or metastatic Urothelial Carcinoma (Keynote-361-AB 54/16 of the AUO)
    Rexer, H.
    Ohlmann, C. -H.
    Retz, M.
    UROLOGE, 2017, 56 (05): : 659 - 661
  • [2] Outcomes by complete response to first-line pembrolizumab or platinum-based chemotherapy in advanced urothelial carcinoma (UC) in KEYNOTE-361
    Ozyilkan, Ozgur
    McDermott, Raymond S.
    Juan-Fita, Maria Jose
    Semenov, Andrey
    Alekseev, Boris
    Berger, Raanan
    Bae, Woo Kyun
    Danchaivijitr, Pongwut
    Lin, Jianxin
    Bavle, Abhishek Amar
    Imai, Kentaro
    Arslan, Cagatay
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [3] Erstlinientherapie beim lokal fortgeschrittenen oder metastasierten UrothelkarzinomEine randomisierte, kontrollierte Phase-III-Studie zum Vergleich von Pembrolizumab mit und ohne platinbasierter Kombinationschemotherapie und der alleinigen Chemotherapie bei Patienten mit fortgeschrittenem oder metastasiertem Urothelkarzinom (Keynote-361 – AB 54/16 der AUO)First-line therapy for locally advanced or metastatic urothelial carcinomaA randomized, controlled phase III trial comparing pembrolizumab with or without platinum-based combination chemotherapy and chemotherapy only in patients with advanced or metastatic urothelial carcinoma (keynote 361—AB 54/16 of the AUO)
    H. Rexer
    C.-H. Ohlmann
    M. Retz
    Der Urologe, 2017, 56 (5): : 659 - 661
  • [4] Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial
    Powles, Thomas
    Csoszi, Tibor
    Ozguroglu, Mustafa
    Matsubara, Nobuaki
    Geczi, Lajos
    Cheng, Susanna Y-S
    Fradet, Yves
    Oudard, Stephane
    Vulsteke, Christof
    Barrera, Rafael Morales
    Flechon, Aude
    Gunduz, Seyda
    Loriot, Yohann
    Rodriguez-Vida, Alejo
    Mamtani, Ronac
    Yu, Evan Y.
    Nam, Kijoeng
    Imai, Kentaro
    Moreno, Blanca Homet
    Alva, Ajjai
    LANCET ONCOLOGY, 2021, 22 (07): : 931 - 945
  • [5] REAL-WORLD RESPONSE TO FIRST LINE PLATINUM-BASED CHEMOTHERAPY IN LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA
    Kim, Sandra
    Ma, Josh
    Eigl, Bernie
    Alimohamed, Nimira
    Kulkarni, Girish
    Chung, Peter
    Graham, Jeffrey
    Breau, Rodney
    Ong, Michael
    Levesque, Eric
    Basappa, Naveen
    Rendon, Ricardo
    Castilloux, Jean
    Winquist, Eric
    Siemens, Robert
    Lattouf, Jean-Baptiste
    Mukherjee, Som
    Yokom, Daniel
    Kassouf, Wassim
    Black, Peter
    JOURNAL OF UROLOGY, 2024, 211 (05): : E863 - E863
  • [6] Efficacy and Tolerability of Tremelimumab in Locally Advanced or Metastatic Urothelial Carcinoma Patients Who Have Failed First-Line Platinum-Based Chemotherapy
    Sharma, Padmanee
    Sohn, Joohyuk
    Shin, Sang Joon
    Oh, Do-Youn
    Keam, Bhumsuk
    Lee, Hyo Jin
    Gizzi, Marco
    Kalinka, Ewa
    de Vos, Filip Y. F. L.
    Ruscica, Dario
    Ferro, Salvatore
    Xiao, Feng
    Baverel, Paul
    Chen, Cecil Chi-Keung
    Asubonteng, Kobby
    Morsli, Nassim
    Dirix, Luc
    CLINICAL CANCER RESEARCH, 2020, 26 (01) : 61 - 70
  • [7] Pembrolizumab (P) combined with chemotherapy (C) vs C alone as first-line (1L) therapy for advanced urothelial carcinoma (UC): KEYNOTE-361
    Alva, A.
    Csoszi, T.
    Ozguroglu, M.
    Matsubara, N.
    Geczi, L.
    Cheng, S. Y-S.
    Fradet, Y.
    Oudard, S.
    Vulsteke, C.
    Morales Barrera, R.
    Flechon, A.
    Gunduz, S.
    Loriot, Y.
    Rodriguez-Vida, A.
    Mamtani, R.
    Yu, E. Y.
    Nam, K.
    Imai, K.
    Moreno, B. H.
    Powles, T. B.
    ANNALS OF ONCOLOGY, 2020, 31 : S1155 - S1155
  • [8] Optimal Number of Cycles of First-line Platinum-based Chemotherapy for Metastatic Urothelial Carcinoma
    Minato, Akinori
    Ohno, Daichi
    Murooka, Kazuki
    Okumura, Yutaka
    Takaba, Tomohisa
    Higashijima, Katsuyoshi
    Nagata, Yujiro
    Tomisaki, Ikko
    Harada, Kenichi
    Fujimoto, Naohiro
    IN VIVO, 2024, 38 (04): : 1927 - 1934
  • [9] THE EFFECTS OF PLATINUM-BASED CHEMOTHERAPY RECHALLENGE FOR ADVANCED UROTHELIAL CARCINOMA PATIENTS WHOSE DISEASE PROGRESSED AFTER FIRST-LINE PLATINUM-BASED CHEMOTHERAPY AND PEMBROLIZUMAB
    Yumioka, Tetsuya
    Honda, Masashi
    Shimizu, Ryutaro
    Teraoka, Shogo
    Kimura, Yusuke
    Iwamoto, Hideto
    Morizane, Shuichi
    Hikita, Katsuya
    Takenaka, Atsushi
    JOURNAL OF UROLOGY, 2021, 206 : E1001 - E1002
  • [10] First-line Maintenance Therapy in adult Patients with locally advanced or metastatic Urothelial Carcinoma who are progression-free after platinum-based Chemotherapy
    Rexer, Heidrun
    Gschwend, Jurgen
    Merseburger, Axel S.
    AKTUELLE UROLOGIE, 2024, 55 (04) : 297 - 298
12345